Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06061952 · ClinicalTrials.gov registry record · NA
CAE for Poorly Adherent Individuals With Schizophrenia
A NA study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT06061952: Completed NA study, sponsored by University Hospitals Cleveland Medical Center.
NCT06061952 is a NA study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06061952, a NA study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Interventions
- BEHAVIORAL Customized Adherence Enhancement for Schizophrenia (CAE-S)
- OTHER Enhanced Treatment as Usual (eTAU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2025-08-09 |
| Phase | NA |
What the finished NCT06061952 record still lists
NCT06061952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Customized Adherence Enhancement for Schizophrenia (CAE-S) is the first listed.
NCT06061952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06061952 about?
NCT06061952 is a clinical study titled "CAE for Poorly Adherent Individuals With Schizophrenia". This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
What is the current status of trial NCT06061952?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2024-01-16. Estimated completion is 2025-08-09.
What interventions are being tested in trial NCT06061952?
The interventions under investigation include: Customized Adherence Enhancement for Schizophrenia (CAE-S) (BEHAVIORAL), Enhanced Treatment as Usual (eTAU) (OTHER).
Who is sponsoring clinical trial NCT06061952?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06061952's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI